|
|
Article: Agreement Between Wyeth-Ayerst Laboratories And Elan Pharmaceutical Will Expand Treatment Options for Americans Suffering from Arthritis Pain
- Article from:
- PR Newswire
- Article date:
- April 10, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IPDAS(TM) Delivery System to Expand Market Potential
for Popular Anti-arthritic, Lodine(R) XL
ATHLONE, Ireland and PHILADELPHIA, April 10 /PRNewswire/ -- Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE: AHP), and Elan Pharmaceutical Technologies, a division of Elan Corporation, plc (NYSE: ELN) have announced an alliance which will expand treatment options for physicians and the 40 million Americans suffering from chronic arthritis pain. Wyeth-Ayerst and Elan have signed a research agreement to develop and market a new once-daily version of the popular arthritis medication Lodine(R) (etodolac ...